TLR3 and neoplasm: Polyriboinosinic‐polyribocytidylic acid (poly(I:C)), a synthetic compound that mimics viral dsRNA polymers, is one of the most extensively studied adjuvants of anti‐tumour vaccines.2 As the ligand of the Toll‐like receptor 3 (TLR3), poly(I:C) triggers the procession and presentation of antigens in innate immune cells, including macrophages and dendritic cells, subsequently leading to anti‐tumour adaptive immunity.3, 4